1.33 USD
-0.07 (-5%)
1.34 USD
+0.01 (+0.75%)
Overall LUCY gets a fundamental rating of 4 out of 10. We evaluated LUCY against 184 industry peers in the Health Care Equipment & Supplies industry. LUCY has a great financial health rating, but its profitability evaluates not so good. LUCY is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year LUCY has reported negative net income.
LUCY had a negative operating cash flow in the past year.
In the past 5 years LUCY always reported negative net income.
LUCY had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
LUCY has a worse Return On Assets (-70.22%) than 73.91% of its industry peers.
LUCY's Return On Equity of -76.56% is in line compared to the rest of the industry. LUCY outperforms 40.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.22% | ||
| ROE | -76.56% | ||
| ROIC | N/A |
ROA(3y)-102.4%
ROA(5y)-213.8%
ROE(3y)-115.52%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 22.83%, LUCY is not doing good in the industry: 79.89% of the companies in the same industry are doing better.
LUCY's Gross Margin has declined in the last couple of years.
LUCY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 22.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.43%
GM growth 5YN/A
2. Health
2.1 Basic Checks
LUCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LUCY has more shares outstanding
The number of shares outstanding for LUCY has been reduced compared to 5 years ago.
There is no outstanding debt for LUCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
LUCY has an Altman-Z score of -0.11. This is a bad value and indicates that LUCY is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.11, LUCY perfoms like the industry average, outperforming 42.93% of the companies in the same industry.
LUCY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.11 |
ROIC/WACCN/A
WACC8.81%
2.3 Liquidity
A Current Ratio of 11.98 indicates that LUCY has no problem at all paying its short term obligations.
LUCY's Current ratio of 11.98 is amongst the best of the industry. LUCY outperforms 94.57% of its industry peers.
LUCY has a Quick Ratio of 10.13. This indicates that LUCY is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 10.13, LUCY belongs to the best of the industry, outperforming 94.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.98 | ||
| Quick Ratio | 10.13 |
3. Growth
3.1 Past
LUCY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.66%, which is quite impressive.
Looking at the last year, LUCY shows a very strong growth in Revenue. The Revenue has grown by 53.21%.
The Revenue has been growing by 33.36% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)72.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.62%
Revenue 1Y (TTM)53.21%
Revenue growth 3Y33.36%
Revenue growth 5YN/A
Sales Q2Q%163.46%
3.2 Future
LUCY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.67% yearly.
The Revenue is expected to grow by 117.64% on average over the next years. This is a very strong growth
EPS Next Y71.92%
EPS Next 2Y36.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year52.63%
Revenue Next 2Y117.64%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
LUCY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LUCY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LUCY's earnings are expected to grow with 36.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.67%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for LUCY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.33
-0.07 (-5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners6.95%
Inst Owner Change97.52%
Ins Owners18.96%
Ins Owner Change-1.08%
Market Cap7.12M
Revenue(TTM)2.39M
Net Income(TTM)-7.85M
Analysts82.86
Price Target3.06 (130.08%)
Short Float %3.75%
Short Ratio0.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.97%
Min EPS beat(2)15.97%
Max EPS beat(2)23.97%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-38.87%
Min Revenue beat(2)-43.24%
Max Revenue beat(2)-34.5%
Revenue beat(4)0
Avg Revenue beat(4)-41.35%
Min Revenue beat(4)-55.39%
Max Revenue beat(4)-32.28%
Revenue beat(8)1
Avg Revenue beat(8)-18.57%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-40%
PT rev (3m)-40%
EPS NQ rev (1m)10.42%
EPS NQ rev (3m)10.42%
EPS NY rev (1m)6.81%
EPS NY rev (3m)15.77%
Revenue NQ rev (1m)-65.71%
Revenue NQ rev (3m)-65.71%
Revenue NY rev (1m)-27.5%
Revenue NY rev (3m)-27.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.97 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.69 | ||
| P/tB | 0.72 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.63
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0.45
BVpS1.92
TBVpS1.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -70.22% | ||
| ROE | -76.56% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 22.83% | ||
| FCFM | N/A |
ROA(3y)-102.4%
ROA(5y)-213.8%
ROE(3y)-115.52%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.43%
GM growth 5YN/A
F-Score3
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 89.89% | ||
| Cap/Sales | 5.5% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 11.98 | ||
| Quick Ratio | 10.13 | ||
| Altman-Z | -0.11 |
F-Score3
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)402.41%
Cap/Depr(5y)N/A
Cap/Sales(3y)23.82%
Cap/Sales(5y)37.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.62%
EPS Next Y71.92%
EPS Next 2Y36.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)53.21%
Revenue growth 3Y33.36%
Revenue growth 5YN/A
Sales Q2Q%163.46%
Revenue Next Year52.63%
Revenue Next 2Y117.64%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-29.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.43%
OCF growth 3YN/A
OCF growth 5YN/A
INNOVATIVE EYEWEAR INC / LUCY FAQ
Can you provide the ChartMill fundamental rating for INNOVATIVE EYEWEAR INC?
ChartMill assigns a fundamental rating of 4 / 10 to LUCY.
What is the valuation status for LUCY stock?
ChartMill assigns a valuation rating of 1 / 10 to INNOVATIVE EYEWEAR INC (LUCY). This can be considered as Overvalued.
What is the profitability of LUCY stock?
INNOVATIVE EYEWEAR INC (LUCY) has a profitability rating of 0 / 10.
What is the financial health of INNOVATIVE EYEWEAR INC (LUCY) stock?
The financial health rating of INNOVATIVE EYEWEAR INC (LUCY) is 7 / 10.
What is the earnings growth outlook for INNOVATIVE EYEWEAR INC?
The Earnings per Share (EPS) of INNOVATIVE EYEWEAR INC (LUCY) is expected to grow by 71.92% in the next year.